1.Study of Morphea.
Korean Journal of Dermatology 1968;6(1):25-28
No abstract available.
Scleroderma, Localized*
2.A Rare Case of Bilateral Frontal Linear Scleroderma (En Coup de Sabre)
Joo Ran HONG ; Ji Su LEE ; Yang Won LEE ; Yong Beom CHOE ; Kyu Joong AHN
Korean Journal of Dermatology 2019;57(6):346-347
No abstract available.
Scleroderma, Localized
3.Transient Bizarre Nystagmus With Frontal Linear Scleroderma With Brain Calcification.
Bek San PARK ; Hyuk Sung KWON ; Jinse PARK ; Hojin CHOI ; Kyu Yong LEE ; Young Joo LEE ; Seong Ho KOH
Journal of the Korean Neurological Association 2012;30(3):241-243
No abstract available.
Brain
;
Scleroderma, Localized
;
Scleroderma, Systemic
4.A Case of Segmental Vitiligo with Generalized Morphea Stabilized by Antimalarial Medication.
Hee Jung KIM ; Dongyun SHIN ; Sang Ho OH
Annals of Dermatology 2016;28(2):249-250
No abstract available.
Scleroderma, Localized*
;
Vitiligo*
5.A Case of Segmental Vitiligo with Generalized Morphea Stabilized by Antimalarial Medication.
Hee Jung KIM ; Dongyun SHIN ; Sang Ho OH
Annals of Dermatology 2016;28(2):249-250
No abstract available.
Scleroderma, Localized*
;
Vitiligo*
6.Linear Scleroderma Clinically Improved with Cyclosporine.
Su Jin OH ; Hyung Kwon PARK ; Young Gyun KIM ; Joung Soo KIM ; Hee Joon YU
Korean Journal of Dermatology 2016;54(6):487-489
No abstract available.
Cyclosporine*
;
Scleroderma, Localized*
7.Linear Scleroderma Clinically Improved with Cyclosporine.
Su Jin OH ; Hyung Kwon PARK ; Young Gyun KIM ; Joung Soo KIM ; Hee Joon YU
Korean Journal of Dermatology 2016;54(6):487-489
No abstract available.
Cyclosporine*
;
Scleroderma, Localized*
8.The pattern of antinuclear antibody and the positive rate of anti-Scl-70 in systemic sclerosis.
Korean Journal of Medicine 2000;58(3):340-341
No abstract available.
Antibodies, Antinuclear*
;
Scleroderma, Systemic*
9.The Frequency of Metabolic Syndrome in Patients with Systemic Sclerosis.
Journal of Rheumatic Diseases 2012;19(6):305-306
No abstract available.
Humans
;
Scleroderma, Systemic
10.Initial studied about role of anti ANA and dsDNA on the patients of scleroderma
Journal of Vietnamese Medicine 2005;309(4):6-9
42 patients were diagnosed as scleroderma and treated at Bach Mai Hospital in three years (1991-1993). 90.47% was female, the age ranged from 18 to 63 years. The control group consisted of 20 healthy normal persons. Results: the rate of anti dsDNA positive with serum 1/10 was 30.95%; the rate of anti ANA positive with serum 1/40 was 71.42% in the patients with scleroderma. In the control group, there is no person who had anti dsDNA positive with serum 1/10. The rate of anti ANA positive with serum 1/40 is 10%. Positive anti dsDNA rate is not high (30.95%). There is no case of scleroderma which had negative anti ANA but positive anti dsDNA in the patients group. The appearance of anti dsDNA and anti ANA with digestive and cardiovascular disorder had a high rate. Anti ANA is more valuable in following the nephroinjuries in the scleroderma than dsDNA
Scleroderma, Systemic
;
Diagnosis
;
Therapeutics
Result Analysis
Print
Save
E-mail